Last reviewed · How we verify
Gliclazide (Comparison drug)
Gliclazide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Gliclazide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Gliclazide (Comparison drug) |
|---|---|
| Sponsor | University of Glasgow |
| Drug class | Sulfonylurea |
| Target | ATP-sensitive potassium channel (KATP channel) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Gliclazide is a meglitinide-class sulfonylurea that binds to ATP-sensitive potassium channels on pancreatic beta cells, causing cell depolarization and opening of voltage-gated calcium channels. This influx of calcium triggers the release of stored insulin into the bloodstream, thereby lowering blood glucose levels in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Gastrointestinal disturbances
- Dizziness
Key clinical trials
- Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients (NA)
- Glucagon in MODY (Maturity Onset Diabetes of the Young) (NA)
- Effect of Anti-diabetic Drugs on Glycemic Variability (PHASE4)
- Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants (PHASE1)
- Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes (PHASE3)
- Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability (PHASE4)
- Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens (EARLY_PHASE1)
- Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gliclazide (Comparison drug) CI brief — competitive landscape report
- Gliclazide (Comparison drug) updates RSS · CI watch RSS
- University of Glasgow portfolio CI